Zhong JX, Rao XQ. NeoHexa stent at five years: Sirolimus power meets real-world endurance. World J Cardiol 2026; 18(7): 117872 [DOI: 10.4330/wjc.117872]
Corresponding Author of This Article
Ji-Xin Zhong, MD, PhD, Chief Physician, Director, Principal Investigator, Professor, Department of Rheumatology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, Fujian Province, China. zhongjixin620@163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jul 26, 2026; 18(7): 117872 Published online Jul 26, 2026. doi: 10.4330/wjc.117872
NeoHexa stent at five years: Sirolimus power meets real-world endurance
Ji-Xin Zhong, Xiao-Quan Rao
Ji-Xin Zhong, Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China
Ji-Xin Zhong, Fujian Institute of Clinical Immunology, Fuzhou 350001, Fujian Province, China
Ji-Xin Zhong, Key Laboratory of Vascular Aging (HUST), Ministry of Education, Wuhan 430030, Hubei Province, China
Xiao-Quan Rao, Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Co-corresponding authors: Ji-Xin Zhong and Xiao-Quan Rao.
Author contributions: Zhong JX drafted the manuscript; Zhong JX and Rao XQ conceived the idea and edited the manuscript as co-corresponding authors; all of the authors read and approved the final version of the manuscript to be published.
AI contribution statement: ChatGPT is only used for language polishing and optimization. This AI tool is not employed for the conception of core ideas or the interpretation of research results.
Supported by the National Key Research and Development Program of China, No. 2023YFC2507902 and No. 2022YFA1105303; National Natural Science Foundation of China, No. 82572075, No. 82270903, and No. 82370465; and Hubei Key R and D Project, No. 2023BCB013.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Corresponding author: Ji-Xin Zhong, MD, PhD, Chief Physician, Director, Principal Investigator, Professor, Department of Rheumatology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, Fujian Province, China. zhongjixin620@163.com
Received: December 18, 2025 Revised: February 3, 2026 Accepted: April 21, 2026 Published online: July 26, 2026 Processing time: 211 Days and 21 Hours
Abstract
The drug-eluting stent, which combines a mechanical scaffold with the localized release of an antiproliferative drug to prevent in-stent restenosis caused by excessive tissue growth, represents a pivotal advancement in percutaneous coronary intervention. In this continually advancing field, establishing long-term efficacy and safety data is paramount. While excellent short-term results are now expected, the true clinical value of a drug-eluting stent is determined by its durability, its ability to maintain vessel patency and prevent adverse cardiac events for many years after implantation, especially in the complex, high-risk patients encountered in real-world practice. The retrospective study by Trehan et al, published in World Journal of Cardiology, provides a much-needed, long-term lens through which to view the performance of the NeoHexa sirolimus-eluting stent in an all-comer real-world Indian population. Here, we will discuss the recent progress in studying the long-term efficacy and safety of sirolimus-eluting stent.
Core Tip: The retrospective study by Trehan et al provides critical five-year real-world evidence for the NeoHexa sirolimus-eluting stent, demonstrating exceptional long-term durability in a complex, all-comer patient population. With a remarkably low rate of major adverse cardiac events and target lesion revascularization, the findings underscore the stent's sustained safety and efficacy.
